Leila Haddad
Partner
Sector
Life Sciences
Biotech, pharmaceutical and medical technology companies, on licensing, financing and regulatory matters.
§ 01Overview
From licensing a molecule to acquiring a commercial-stage company, we advise life sciences businesses and their investors on the transactions, collaborations and regulatory questions that shape a product's path to patients.
§ 02Key contacts
Key contacts
Isabel Ortega
Partner
§ 03Experience
Representative matters
Prior results do not guarantee a similar outcome.
Advised Osric Therapeutics on its sale to Pendray Life Sciences
Negotiated the merger agreement and contingent value rights for a clinical-stage biotech, with antitrust clearance in the US and UK.
Mergers & Acquisitions · Antitrust & Competition
US$2.1 billion
Led the audit committee's investigation at Brevik Medical Systems
Conducted an internal investigation into distributor payments and represented the company before federal prosecutors, which closed the matter without charges.
Investigations & White Collar
Responded to a data protection authority inquiry after a ransomware incident
Coordinated incident response, notifications and the regulatory inquiry for a healthcare technology company.
Data, Privacy & Technology · Investigations & White Collar
§ 04Insights
Related insights
Earn-outs: drafting for the dispute you hope never comes
An earn-out bridges a valuation gap at signing and often reopens it two years later. The drafting decides who wins that argument.
Preparing for a second request: a timeline for merging parties
An in-depth merger review is a project with a timetable. Parties who plan it from the term sheet keep control of it.
Internal investigations: the first seventy-two hours
Decisions made in the first days of an investigation are hard to undo. A checklist for general counsel.
§ 05Related